Structural and Mechanistic Insights into 4′-Dehydrogenation Catalyzed by AprD5 in Apramycin Biosynthesis
Structural and Mechanistic Insights into 4′-Dehydrogenation Catalyzed by AprD5 in Apramycin Biosynthesis
Abstract. AprD5 is a member of the NAD+-dependent short-chain dehydrogenase/reductase (SDR) superfamily. It participates in the apramycin biosynthetic path
pubs.acs.org
September 25, 2026 at 10:15 AM
Structural and Mechanistic Insights into 4′-Dehydrogenation Catalyzed by AprD5 in Apramycin Biosynthesis
ST11 is notorious for jumping between pigs and people (pubmed.ncbi.nlm.nih.gov/30992351/). Because pigs are routinely treated with apramycin (a vet‑only aminoglycoside) we asked whether apramycin selected, npmA2‑positive ST11 strains in pigs might spill over into people 🐖 🧑🌾 (6/14)
July 17, 2025 at 12:13 PM
ST11 is notorious for jumping between pigs and people (pubmed.ncbi.nlm.nih.gov/30992351/). Because pigs are routinely treated with apramycin (a vet‑only aminoglycoside) we asked whether apramycin selected, npmA2‑positive ST11 strains in pigs might spill over into people 🐖 🧑🌾 (6/14)
New @US-Pharmacopeia reference standards and Quality Solution Sheets are available at @Labmix24. Learn more: labmix24.com/en/pharmaceu...
#pharmaceuticals #qualityassurance
#pharmaceuticalmanufacturing
#Adenosine #Apramycin # Bexarotene #Clioquinol #Colistimethate #Ketotifen #Pimecrolimus
#pharmaceuticals #qualityassurance
#pharmaceuticalmanufacturing
#Adenosine #Apramycin # Bexarotene #Clioquinol #Colistimethate #Ketotifen #Pimecrolimus
January 22, 2024 at 9:56 AM
New @US-Pharmacopeia reference standards and Quality Solution Sheets are available at @Labmix24. Learn more: labmix24.com/en/pharmaceu...
#pharmaceuticals #qualityassurance
#pharmaceuticalmanufacturing
#Adenosine #Apramycin # Bexarotene #Clioquinol #Colistimethate #Ketotifen #Pimecrolimus
#pharmaceuticals #qualityassurance
#pharmaceuticalmanufacturing
#Adenosine #Apramycin # Bexarotene #Clioquinol #Colistimethate #Ketotifen #Pimecrolimus
Apramycin efficacy in the treatment of carbapenem-resistant Enterobacterales in murine blood stream infection models https://www.biorxiv.org/content/10.1101/2023.12.10.570991v1
Apramycin efficacy in the treatment of carbapenem-resistant Enterobacterales in murine blood stream infection models https://www.biorxiv.org/content/10.1101/2023.12.10.570991v1
Background: The aminoglycoside apramycin has been proposed as a drug candidate for the treatment of
www.biorxiv.org
December 11, 2023 at 3:19 AM
Apramycin efficacy in the treatment of carbapenem-resistant Enterobacterales in murine blood stream infection models https://www.biorxiv.org/content/10.1101/2023.12.10.570991v1
Putting it all together 🏁:
- npmA2 is located on an ICE that seems to transfer only rarely (lab and database evidence)
- C. diff ST11 has picked it up multiple times, perhaps in pig guts under apramycin pressure (hypothesis)
- One hospital crossover has already moved npmA2 into E. faecium (10/14)
- npmA2 is located on an ICE that seems to transfer only rarely (lab and database evidence)
- C. diff ST11 has picked it up multiple times, perhaps in pig guts under apramycin pressure (hypothesis)
- One hospital crossover has already moved npmA2 into E. faecium (10/14)
July 17, 2025 at 12:13 PM
Putting it all together 🏁:
- npmA2 is located on an ICE that seems to transfer only rarely (lab and database evidence)
- C. diff ST11 has picked it up multiple times, perhaps in pig guts under apramycin pressure (hypothesis)
- One hospital crossover has already moved npmA2 into E. faecium (10/14)
- npmA2 is located on an ICE that seems to transfer only rarely (lab and database evidence)
- C. diff ST11 has picked it up multiple times, perhaps in pig guts under apramycin pressure (hypothesis)
- One hospital crossover has already moved npmA2 into E. faecium (10/14)
“GARDP said today that it has acquired all data and licensing rights for apramycin, an aminoglycoside antibiotic introduced in the early 1980s to treat gram-negative bacterial infections in animals.” www.cidrap.umn.edu/antimicrobia...
GARDP to explore animal antibiotic as a potential superbug treatment
GARDP has acquired all data and licensing rights for apramycin, an aminoglycoside antibiotic used in veterinary medicine, and will evaluate its potential to treat highly drug-resistant infections in p...
www.cidrap.umn.edu
March 5, 2026 at 11:16 PM
“GARDP said today that it has acquired all data and licensing rights for apramycin, an aminoglycoside antibiotic introduced in the early 1980s to treat gram-negative bacterial infections in animals.” www.cidrap.umn.edu/antimicrobia...
@gardp.bsky.social recently announced that it has acquired all data/licensing rights for apramycin, an antibiotic for serious bacterial infections in animals, to evaluate its potential as an antibiotic against drug-resistant infections in humans. #AMR
www.ghtcoalition.org/blog/researc...
www.ghtcoalition.org/blog/researc...
Research Roundup: Sleeping sickness drug endorsement, Potential superbug treatment, New drug-resistant bacteria approach
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
www.ghtcoalition.org
March 12, 2026 at 1:27 PM
@gardp.bsky.social recently announced that it has acquired all data/licensing rights for apramycin, an antibiotic for serious bacterial infections in animals, to evaluate its potential as an antibiotic against drug-resistant infections in humans. #AMR
www.ghtcoalition.org/blog/researc...
www.ghtcoalition.org/blog/researc...
Metformin not effective in treating long-COVID symptoms, study finds
->Center for Infectious Disease Research and Policy | More info at BigEarthData.ai
->Center for Infectious Disease Research and Policy | More info at BigEarthData.ai
Metformin not effective in treating long-COVID symptoms, study finds
The Global Antibiotic Research and Development Partnership (GARDP) is looking into the potential of an older antibiotic used exclusively in veterinary medicine to treat highly drug-resistant infections in people. GARDP said today that it has acquired all data and licensing rights for apramycin, an aminoglycoside antibiotic introduced in the early 1980s to treat gram-negative bacterial infections in animals. Bought from Swiss drugmaker Juvabis AG after it closed in 2025, the drug has shown potential for human use in preclinical trials. Apramycin is one of several therapies GARDP is evaluating for drug-resistant gram-negative bacteria, which are a significant driver of deaths caused by bacterial infections and are becoming increasingly resistant to antibiotics. Several gram-negative species have been targeted by the World Health Organizations as “priority pathogens” for antibiotic development. Phase 1 study planned GARDP officials say apramycin’s distinct chemical structure enables it to evade the resistance mechanisms that undermine other aminoglycoside antibiotics. A phase 1 study to assess safety and pharmacokinetics is planned for 2027...
www.cidrap.umn.edu
March 5, 2026 at 6:29 PM
Enhanced Activity of Apramycin and Apramycin-Based Combinations Against Mycobacteroides abscessus https://www.biorxiv.org/content/10.1101/2025.04.09.648020v1
April 10, 2025 at 2:18 AM
Enhanced Activity of Apramycin and Apramycin-Based Combinations Against Mycobacteroides abscessus https://www.biorxiv.org/content/10.1101/2025.04.09.648020v1
Apramycin resistance in bacteria isolated from humans, a systematic review and meta-analysis https://www.medrxiv.org/content/10.1101/2025.10.20.25338358v1
October 21, 2025 at 5:43 PM
Apramycin resistance in bacteria isolated from humans, a systematic review and meta-analysis https://www.medrxiv.org/content/10.1101/2025.10.20.25338358v1
Enhanced Activity of Apramycin and Apramycin-Based Combinations Against Mycobacteroides abscessus https://www.biorxiv.org/content/10.1101/2025.04.09.648020v1
April 10, 2025 at 2:18 AM
Enhanced Activity of Apramycin and Apramycin-Based Combinations Against Mycobacteroides abscessus https://www.biorxiv.org/content/10.1101/2025.04.09.648020v1
Apramycin efficacy in the treatment of carbapenem-resistant Enterobacterales in murine blood stream infection models https://www.biorxiv.org/content/10.1101/2023.12.10.570991v1
Apramycin efficacy in the treatment of carbapenem-resistant Enterobacterales in murine blood stream infection models https://www.biorxiv.org/content/10.1101/2023.12.10.570991v1
Background: The aminoglycoside apramycin has been proposed as a drug candidate for the treatment of
www.biorxiv.org
December 11, 2023 at 3:19 AM
Apramycin efficacy in the treatment of carbapenem-resistant Enterobacterales in murine blood stream infection models https://www.biorxiv.org/content/10.1101/2023.12.10.570991v1
🧪GARDP has acquired data & licensing rights for the human use of apramycin, a potential treatment for drug-resistant Gram-negative infections.
With rights secured via Zurich University, a 2027 Phase 1 study is planned to assess safety & pharmacokinetics in humans.
🔗https://bit.pulse.ly/9shbh5zy0j
With rights secured via Zurich University, a 2027 Phase 1 study is planned to assess safety & pharmacokinetics in humans.
🔗https://bit.pulse.ly/9shbh5zy0j
March 5, 2026 at 8:31 AM
🧪GARDP has acquired data & licensing rights for the human use of apramycin, a potential treatment for drug-resistant Gram-negative infections.
With rights secured via Zurich University, a 2027 Phase 1 study is planned to assess safety & pharmacokinetics in humans.
🔗https://bit.pulse.ly/9shbh5zy0j
With rights secured via Zurich University, a 2027 Phase 1 study is planned to assess safety & pharmacokinetics in humans.
🔗https://bit.pulse.ly/9shbh5zy0j
In 2025, we:
💉 Advanced NeoSep1 in Africa, enrolling newborns in South Africa (SA)
🔬 Expanded Bugworks partnership on BWC0977
🌍 Expanded cefiderocol access in Kenya, India, SA & Brazil
🤝 Formed new partnership with Debiopharm to explore new gonorrhoea treatments
🚀 Secured apramycin for our pipeline
💉 Advanced NeoSep1 in Africa, enrolling newborns in South Africa (SA)
🔬 Expanded Bugworks partnership on BWC0977
🌍 Expanded cefiderocol access in Kenya, India, SA & Brazil
🤝 Formed new partnership with Debiopharm to explore new gonorrhoea treatments
🚀 Secured apramycin for our pipeline
December 17, 2025 at 8:14 AM
In 2025, we:
💉 Advanced NeoSep1 in Africa, enrolling newborns in South Africa (SA)
🔬 Expanded Bugworks partnership on BWC0977
🌍 Expanded cefiderocol access in Kenya, India, SA & Brazil
🤝 Formed new partnership with Debiopharm to explore new gonorrhoea treatments
🚀 Secured apramycin for our pipeline
💉 Advanced NeoSep1 in Africa, enrolling newborns in South Africa (SA)
🔬 Expanded Bugworks partnership on BWC0977
🌍 Expanded cefiderocol access in Kenya, India, SA & Brazil
🤝 Formed new partnership with Debiopharm to explore new gonorrhoea treatments
🚀 Secured apramycin for our pipeline